CN | EN
ABOUT US
2017
2018
2019
2020
2021
2022
2023
2017
Dec, BioCity founded
2018
Early drug discovery
2019
Early drug discovery
Dec, First IND approval by the NMPA( No. BC3425)
2020
Completed series A financing
Jun, Second IND approval by the NMPA ( No.SC0062)
Sep, Third IND approval by the NMPA (No.BC3402)
Oct, Fourth IND approval by the NMPA (No.SC0245)
Nov, Fifth IND approval by the NMPA (No.SC0191)
2021
Sep, Co-CEO & CMO Dr. Yong Jiang Hei Joined the company
Oct, Wuxi Translational Medicine Center in operation
Nov, Strategic framework agreement signed with AstraZeneca
Nov, Initiated the construction of the first phase I clinical trial base
2022
Jan, First patient Dosing in CD3/EGFR BsAb BC3448 Phase Ⅰ trial
Jul, the second indication (SCLC) of SC0245 approval by NMPA
Dec,the Phase 2 trial application (IgA & DKD)of SC0062 approved by NMPA
Dec, The first IND(Malignant hematology) approval by FDA (No.BC3402)
Dec, The third indication(Malignant hematology) of BC3402 approval by NMPA
Dec, The third indication( Ovarian Cancer )of SC0191 approval by NMPA
Shanghai R&D Center and Lab in operation
2023
Feb, Phase 1/2 trial of SC0191 approval by FDA
Feb, Phase 1 trial application of FIC ADC(CDH3) BC3195 approval by FDA